Lunit, a medical artificial intelligence (AI) company, announced on Monday that it has expanded its global supply chain by securing contracts for AI and digital solutions with major healthcare institutions in the United Kingdom and the U.S.
The company recently added GenesisCare UK, which operates over ten premium cancer and diagnostic centers across Britain, to its client roster, broadening its European customer base.
As part of these agreements, Lunit will provide its analytics and scorecard solutions for mammography quality and operations management, along with its AI-powered breast cancer diagnostic tools, Lunit Insight MMG and Lunit Insight DBT.
Digital Breast Tomosynthesis (DBT) is an advanced imaging technique that captures multiple angles of the breast to reconstruct a three-dimensional (3D) image.
In the U.S., VA Tulsa, a medical facility under the Department of Veterans Affairs, has become a new client. This large care center serves approximately 36,000 veterans annually.
This latest contract with the VA follows Lunit’s 7.3 million USD deal with the Defense Health Agency (DHA) in 2024, secured through its subsidiary Lunit International (formerly Volpara). These agreements significantly strengthen Lunit’s foothold in the U.S. public healthcare sector.
For VA Tulsa, Lunit plans to implement its patient hub, which streamlines appointment scheduling, tracking, and result notifications. The facility will also receive Lunit’s risk pathway tool, designed to identify high-risk individuals and tailor screening programs accordingly.
Lunit has also inked a new contract with the Ditar Healthcare System, a comprehensive hospital network in Texas.
With over 200 specialists and medical professionals, Ditar Healthcare System will integrate Lunit’s patient hub and risk pathway to enhance patient management and develop a more sophisticated, risk-based personalized screening system.
Lunit Chief Executive Officer (CEO) Seo Beom-seok commented that these contracts underscore the rapidly growing global demand for comprehensive cancer screening platforms. It’s committed to expanding the presence in the international healthcare market by leveraging the unique product mix of AI-powered imaging and advanced screening operation solutions.